A vaccine targeting mutant IDH1 in newly diagnosed glioma.

doi:10.1038/s41586-021-03363-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A vaccine targeting mutant IDH1 in newly diagnosed glioma.

Nature - 1 Apr 2021

Platten Michael, Bunse Lukas, Wick Antje, Bunse Theresa, Le Cornet Lucian, Harting Inga, Sahm Felix, Sanghvi Khwab, Tan Chin Leng, Poschke Isabel, Green Edward, Justesen Sune, Behrens Geoffrey A, Breckwoldt Michael O, Freitag Angelika, Rother Lisa-Marie, Schmitt Anita, Schnell Oliver, Hense Jörg, Misch Martin, Krex Dietmar, Stevanovic Stefan, Tabatabai Ghazaleh, Steinbach Joachim P, Bendszus Martin, von Deimling Andreas, Schmitt Michael, Wick Wolfgang

Abstract excerpt

Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma1-3. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II4,5. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutant Proteins

Share to Receptors, Antigen, T-Cell

Share to Survival Rate

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 33762734
DOI: 10.1038/s41586-021-03363-z
PMCID: PMC8046668

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A vaccine targeting mutant IDH1 in newly diagnosed glioma.PMID 33762734Read ↗

A vaccine targeting mutant IDH1 induces antitumour immunity.Semantic proximity Read ↗

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Semantic proximity Read ↗

In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.Semantic proximity Read ↗

Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma.Semantic proximity Read ↗

A Specific Peptide Vaccine Against IDH1(R132H) Glioma.Semantic proximity Read ↗

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trialsSemantic proximity Read ↗

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.Semantic proximity Read ↗

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.Semantic proximity Read ↗

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.Semantic proximity Read ↗

A first-in-human peptide vaccine targeting H3K27M; encouraging early findings in 8 adults with diffuse midline glioma.Semantic proximity Read ↗

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of GlioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.